This report examines the rapid expansion of digital health tools, including mobile apps, wearables, and digital therapeutics, positioning them as a new therapeutic modality. Over 350,000 digital health apps are available globally, with growth focused on disease management, mental health, diabetes, and cardiovascular care. The report assesses evidence maturity, noting growth in randomized studies and systematic reviews, alongside emerging regulatory and reimbursement pathways. It highlights increasing use of digital biomarkers and decentralized clinical trials, accelerated by COVID-19. While adoption is growing among payers and employers, barriers remain around integration, standards, and reimbursement, which are gradually being addressed.

Join for free to read